Author:
Bruyere Olivier,Cooper Cyrus,Pavelka Karel,Rabenda Véronique,Buckinx Fanny,Beaudart Charlotte,Reginster Jean-Yves
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism
Reference23 articles.
1. European Medicines Agency (2010) Guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis. www.ema.europa.eu . Accessed 18 Jan 2013
2. Food and Drug Administration (2011) Guidance for industry. Clinical development programs for drugs, devices, and biological products intended for the treatment of osteoarthritis. www.fda.gov . Accessed 18 Jan 2013
3. Beaton DE, Bombardier C, Katz JN, Wright JG (2001) A taxonomy for responsiveness. J Clin Epidemiol 54:1204–1217
4. Ornetti P, Brandt K, Hellio-Le Graverand MP, Hochberg M, Hunter DJ, Kloppenburg M, Lane N, Maillefert JF, Mazzuca SA, Spector T, Utard-Wlerick G, Vignon E, Dougados M (2009) OARSI-OMERACT definition of relevant radiological progression in hip/knee osteoarthritis. Osteoarthritis Cartilage 17:856–863
5. Manno RL, Bingham CO 3rd, Paternotte S, Gossec L, Halhol H, Giacovelli G, Rovati L, Mazzuca SA, Clegg DO, Shi H, Tajana Messi E, Lanzarotti A, Dougados M (2012) OARSI-OMERACT initiative: defining thresholds for symptomatic severity and structural changes in disease modifying osteoarthritis drug (DMOAD) clinical trials. Osteoarthritis Cartilage 20:93–101
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献